Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects

Oleg E Osadchii1

  • 1Cardiology Group, School of Clinical Sciences, University Clinical Departments, University of Liverpool, The Duncan Building, Daulby Street, Liverpool, L69 3GA, UK. osadchii@mail.ru

Heart Failure Reviews
|March 28, 2007
PubMed

Insights

Sustained beta-adrenoreceptor activation promotes cardiac hypertrophy through various molecular pathways. While initially preserving function, further progression leads to heart failure due to calcium handling issues and fibrosis.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Cardiac hypertrophy, driven by adrenergic over-activation, is a major risk factor for cardiovascular disease.
  • Understanding the mechanisms of myocardial growth and functional changes in hypertrophy is crucial.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying catecholamine-induced cardiac hypertrophy.
  • To investigate the functional consequences of structural changes in hypertrophied myocardium.

Main Methods:

  • Utilized an animal model of chronic systemic beta-adrenoreceptor agonist administration.
  • Analyzed molecular signaling pathways including growth factors, proto-oncogenes, oxidative stress, MAPKs, and PI3K.
  • Assessed cardiac autonomic regulation and beta-adrenoreceptor function.

Main Results:

  • Sustained beta-adrenoreceptor activation enhances myocardial protein synthesis and promotes cardiac hypertrophy.
  • Hypertrophy is associated with impaired autonomic regulation and altered beta-adrenoreceptor signaling.
  • Compensated hypertrophy shows preserved systolic function via enhanced calcium handling, but progresses to heart failure due to calcium abnormalities and fibrosis.

Conclusions:

  • Adrenergic over-activation is a key driver of cardiac hypertrophy with complex molecular underpinnings.
  • Early stages of hypertrophy may involve compensatory mechanisms, but progression leads to functional decline and heart failure.
  • Targeting these pathways may offer therapeutic strategies for managing cardiac hypertrophy and heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...